• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Bellerophon raises $3m in direct offering

May 11, 2017 By Sarah Faulkner

Bellerophon TherapeuticsBellerophon Therapeutics (NSDQ:BLPH) said yesterday that it inked a $3 million direct offering of common stock with a single, unnamed institutional investor. The offering is expected to close by the beginning of next week.

Warren, N.J.-based Bellerophon plans to issue 2 million registered shares of common stock at $1.50 apiece in connection with the offering.

In a private placement, the company said it will also issue warrants to purchase up to 1 million shares of common stock. For each share of common stock purchased in the direct offering, such investor in a private placement will receive an unregistered warrant to purchase 0.50 share of common stock.

The warrants have an exercise price of $1.50 per share and will be exercisable 6 months after the issue date, according to Bellerophon.

The company said it plans to use the offering’s net proceeds for general corporate purposes, including expenses relating to manufacturing and clinical trials.

In April, Bellerophon presented data for its INOpulse nitric oxide device in patients with pulmonary arterial hypertension at the International Society of Heart and Lung Transplantation’s annual meeting.

Researchers studied the effects of pulsed inhaled nitric oxide, delivered by the INOpulse device in 10 patients with pulmonary arterial hypertension both before and after exercise.

Patients who received inhaled nitric oxide consistently improved in regards to “at rest” measurements of pulmonary arterial pressure, cardiac index, RV stroke work index and effective compliance. Researchers said this trend was preserved with exercise when compared to patients who did not receive inhaled nitric oxide.

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Funding Roundup, Wall Street Beat Tagged With: Bellerophon Therapeutics

IN CASE YOU MISSED IT

  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement
  • Insulet earnings trounce Q3 estimates as it narrows guidance
  • Dexcom Q3 earnings top forecasts, as it looks ahead to type 2 coverage

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS